In an era of rapid disruption, static data is no longer enough. We bridge the gap between complex market data and actionable strategy through our unique RaaS (Research-as-a-Service) framework. Explore our latest Industry Intelligence Briefings, methodology deep-dives, and expert analysis designed to provide the clarity you need for high-stakes board presentations, acquisition due diligence, and long-term strategic planning. Need specific answers? Commission a bespoke intelligence study tailored to your requirements.
A real 2025 divestiture at Kyowa Hakko Bio and an independently-confirmed ownership correction at KOHJIN Life Sciences together clarify wher…
No manufacturer discloses Alanyl-Glutamine-specific revenue. We built an independent market-size estimate anyway -- and found a real regiona…
Why a tablet made in Hyderabad might be exported to Lagos while an identical one stays in Mumbai -- and why sizing India's pharmaceutical in…
Real, verified FY2026 rankings of India's top pharma companies by both revenue and manufacturing/export scale -- two genuinely different lis…
ADCs are growing at 18% CAGR inside an oncology market averaging 11% overall — and Keytruda's patent cliff hits just as that wave reaches fu…
Oral semaglutide is already commercial. A five-company pipeline of dual-agonist and biosimilar challengers is advancing behind it. Inside th…
Eli Lilly's market cap crossed $1 trillion in August 2026 - the first healthcare company ever to do so. Inside the $1.65T global pharmaceuti…
With the market's underlying forecast pointing toward $2.45 trillion by 2031, and every one of the top 10 companies now navigating some comb…
Why a single tablet might involve chemistry in China, formulation in India, and consumption in the United States — and why market sizing the…
The single largest driver of pharmaceutical market growth today is the GLP-1 receptor agonist and broader cardiometabolic therapy revolution…
